NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K Filing
NeOnc receives FDA written feedback on CMC development for NEO212 and capsule-to-tablet transition (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $NTHI
NeOnc receives FDA written feedback on CMC development for NEO212 and capsule-to-tablet transition (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $NTHI